Structure Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Structure Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||
| current assets: | |||||||||||
| cash and cash equivalents | 147,024,000 | 152,123,000 | 169,510,000 | 172,130,000 | 381,627,000 | 97,832,000 | 129,792,000 | 50,636,000 | 40,591,000 | 126,493,000 | 26,091,000 |
| short-term investments | 639,472,000 | 684,759,000 | 714,008,000 | 743,156,000 | 545,492,000 | 338,617,000 | 337,531,000 | 154,788,000 | 183,996,000 | 114,369,000 | 64,750,000 |
| prepaid expenses and other current assets | 12,802,000 | 12,740,000 | 7,693,000 | 8,365,000 | 10,502,000 | 12,911,000 | 6,285,000 | 4,535,000 | 3,635,000 | 5,293,000 | 2,248,000 |
| total current assets | 799,298,000 | 849,622,000 | 891,211,000 | 923,651,000 | 937,621,000 | 449,360,000 | 473,608,000 | 209,959,000 | 228,222,000 | 246,155,000 | 93,089,000 |
| property and equipment | 3,459,000 | 3,518,000 | 3,478,000 | 3,735,000 | 3,315,000 | 3,120,000 | 3,228,000 | 2,408,000 | 1,078,000 | 961,000 | 1,031,000 |
| operating right-of-use assets | 7,484,000 | 7,313,000 | 3,535,000 | 4,009,000 | 4,267,000 | 4,698,000 | 5,136,000 | 3,653,000 | 90,000 | 178,000 | 262,000 |
| other non-current assets | 6,202,000 | 6,096,000 | 5,106,000 | 1,822,000 | 1,826,000 | 47,000 | 45,000 | 350,000 | 38,000 | 59,000 | 3,463,000 |
| total assets | 816,443,000 | 866,549,000 | 903,330,000 | 933,217,000 | 947,029,000 | 457,225,000 | 482,017,000 | 216,370,000 | 229,428,000 | 247,353,000 | 97,845,000 |
| liabilities and shareholders’ equity | |||||||||||
| current liabilities: | |||||||||||
| accounts payable | 8,990,000 | 8,710,000 | 8,024,000 | 8,447,000 | 2,209,000 | 6,538,000 | 4,742,000 | 3,319,000 | 5,699,000 | 4,945,000 | 6,009,000 |
| accrued expenses and other current liabilities | 27,379,000 | 25,306,000 | 26,299,000 | 23,275,000 | 18,821,000 | 15,448,000 | 18,558,000 | 15,955,000 | 9,241,000 | 5,889,000 | 6,741,000 |
| operating lease liabilities, current portion | 2,664,000 | 2,471,000 | 1,698,000 | 1,712,000 | 1,629,000 | 1,600,000 | 1,440,000 | 817,000 | 73,000 | 168,000 | 260,000 |
| total current liabilities | 39,033,000 | 36,487,000 | 36,021,000 | 33,434,000 | 22,659,000 | 23,586,000 | 24,740,000 | 20,091,000 | 15,013,000 | 11,002,000 | 13,010,000 |
| operating lease liabilities, net of current portion | 5,012,000 | 5,116,000 | 2,164,000 | 2,673,000 | 3,045,000 | 3,525,000 | 4,013,000 | 3,034,000 | |||
| other non-current liabilities | 317,000 | 308,000 | 302,000 | 309,000 | 293,000 | 296,000 | 298,000 | 281,000 | |||
| total liabilities | 44,362,000 | 41,911,000 | 38,487,000 | 36,416,000 | 25,997,000 | 27,407,000 | 29,051,000 | 23,406,000 | 15,013,000 | 11,002,000 | 13,010,000 |
| commitments and contingencies | |||||||||||
| shareholders’ equity: | |||||||||||
| undesignated shares – 0.0001 par value; 100,000 shares authorized as of june 30, 2025 and december 31, 2024 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of june 30, 2025 and december 31, 2024; 172,700 and 171,860 shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 17,000 | ||||||||||
| additional paid-in capital | 1,209,294,000 | 1,199,737,000 | 1,193,010,000 | 1,186,564,000 | 1,180,144,000 | 662,502,000 | 659,003,000 | 375,332,000 | 373,001,000 | 371,120,000 | 1,921,000 |
| accumulated other comprehensive income | 362,000 | 815,000 | 914,000 | 2,839,000 | -487,000 | -90,000 | 521,000 | 147,000 | |||
| accumulated deficit | -437,592,000 | -375,931,000 | -329,098,000 | -292,619,000 | -258,642,000 | -232,608,000 | -206,572,000 | -182,069,000 | -158,207,000 | -134,927,000 | -116,952,000 |
| total shareholders’ equity | 772,081,000 | 824,638,000 | 864,843,000 | 896,801,000 | 921,032,000 | 429,818,000 | 452,966,000 | 192,964,000 | 214,415,000 | 236,351,000 | |
| total liabilities and shareholders’ equity | 816,443,000 | 866,549,000 | 903,330,000 | 933,217,000 | 947,029,000 | 457,225,000 | |||||
| | 2,022,000 | ||||||||||
| undesignated shares – 0.0001 par value; 100,000 shares authorized as of march 31, 2025 and december 31, 2024 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of march 31, 2025 and december 31, 2024; 172,610 and 171,860 shares issued and outstanding as of march 31, 2025 and december 31, 2024, respectively | 17,000 | ||||||||||
| undesignated shares – 0.0001 par value; 100,000 shares authorized as of december 31, 2024 and december 31, 2023 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of december 31, 2024 and december 31, 2023; 171,860 and 139,220 shares issued and outstanding as of december 31, 2024 and december 31, 2023, respectively | 17,000 | ||||||||||
| undesignated shares – 0.0001 par value; 100,000 shares authorized as of september 30, 2024 and december 31, 2023 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of september 30, 2024 and december 31, 2023; 171,762 and 139,220 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | 17,000 | ||||||||||
| undesignated shares – 0.0001 par value; 100,000 shares authorized as of june 30, 2024 and december 31, 2023 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of june 30, 2024 and december 31, 2023; 171,589 and 139,220 shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively | 17,000 | ||||||||||
| undesignated shares – 0.0001 par value; 90,188 and 90,188 shares authorized as of march 31, 2024 and december 31, 2023, respectively | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 shares authorized as of march 31, 2024 and december 31, 2023; 139,855 and 139,220 shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively | 14,000 | ||||||||||
| liabilities, redeemable convertible preferred shares and shareholders’ equity | |||||||||||
| series a redeemable convertible preferred shares – 0.0001 par value, 0 and 19,200 shares authorized, issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | |||||||||||
| series a+ redeemable convertible preferred shares – 0.0001 par value, 0 and 12,800 shares authorized, issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | |||||||||||
| series b redeemable convertible preferred stock – 0.0001 par value, 0 and 32,857 shares authorized, issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | |||||||||||
| series b‑1 redeemable convertible preferred stock – 0.0001 par value, 0 and 2,161 shares authorized, issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | |||||||||||
| shareholders’ equity | |||||||||||
| undesignated shares – 0.0001 par value; 90,188 and 0 shares authorized as of december 31, 2023 and december 31, 2022, respectively | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 and 432,982 shares authorized as of december 31, 2023 and december 31, 2022, respectively; 139,220 and 10,527 shares issued and outstanding as of december 31, 2023 and december 31, 2022, respectively | 14,000 | ||||||||||
| total liabilities, redeemable convertible preferred shares and shareholders’ equity | 482,017,000 | 216,370,000 | 229,428,000 | 247,353,000 | |||||||
| series a redeemable convertible preferred shares – 0.0001 par value, 0 and 19,200 shares authorized, issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| series a+ redeemable convertible preferred shares – 0.0001 par value, 0 and 12,800 shares authorized, issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b redeemable convertible preferred stock – 0.0001 par value, 0 and 32,857 shares authorized, issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b‑1 redeemable convertible preferred stock – 0.0001 par value, 0 and 2,161 shares authorized, issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| undesignated shares – 0.0001 par value; 100,000 and 0 shares authorized as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| non-voting ordinary shares – 0.0001 par value; 7,411 and 0 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | 1,000 | ||||||||||
| ordinary shares – 0.0001 par value; 500,000 and 432,982 shares authorized as of september 30, 2023 and december 31, 2022, respectively; 107,723 and 10,527 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | 10,000 | ||||||||||
| accumulated other comprehensive loss | -310,000 | -390,000 | -110,000 | ||||||||
| series a redeemable convertible preferred shares – 0.0001 par value, 0 and 19,200 shares authorized, issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| series a+ redeemable convertible preferred shares – 0.0001 par value, 0 and 12,800 shares authorized, issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b redeemable convertible preferred stock – 0.0001 par value, 0 and 32,857 shares authorized, issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b‑1 redeemable convertible preferred stock – 0.0001 par value, 0 and 2,161 shares authorized, issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| undesignated shares – 0.0001 par value; 100,000 and 0 shares authorized as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| non-voting ordinary shares – 0.0001 par value; 7,411 and 0 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | 1,000 | ||||||||||
| ordinary shares – 0.0001 par value; 500,000 and 432,982 shares authorized as of june 30, 2023 and december 31, 2022, respectively; 107,387 and 10,527 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | 10,000 | ||||||||||
| series a redeemable convertible preferred shares – 0.0001 par value, 0 and 19,200 shares authorized, issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| series a+ redeemable convertible preferred shares – 0.0001 par value, 0 and 12,800 shares authorized, issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| series b redeemable convertible preferred stock – 0.0001 par value, 0 and 32,857 shares authorized, issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| series b‑1 redeemable convertible preferred stock – 0.0001 par value, 0 and 2,161 shares authorized, issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| undesignated shares – 0.0001 par value; 100,000 and 0 shares authorized as of march 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||
| ordinary shares – 0.0001 par value; 500,000 and 432,982 shares authorized as of march 31, 2023 and december 31, 2022, respectively; 114,730 and 10,527 shares issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | 11,000 | ||||||||||
| liabilities, redeemable convertible preferred shares and shareholders’ deficit | |||||||||||
| series a redeemable convertible preferred shares – 0.0001 par value, 19,200 shares authorized, issued and outstanding as of december 31, 2022 and 2021 | 32,001,000 | ||||||||||
| series a+ redeemable convertible preferred shares – 0.0001 par value, 12,800 shares authorized, issued and outstanding as of december 31, 2022 and 2021 | 26,000,000 | ||||||||||
| series b redeemable convertible preferred stock – 0.0001 par value, 32,857 and 24,702 shares authorized, issued and outstanding as of december 31, 2022 and 2021, respectively | 133,015,000 | ||||||||||
| series b‑1 redeemable convertible preferred stock – 0.0001 par value, 2,161 shares authorized, issued and outstanding as of december 31, 2022 and 2021 | 8,959,000 | ||||||||||
| shareholders’ deficit: | |||||||||||
| ordinary shares – 0.0001 par value; 432,982 and 441,137 shares authorized as of december 31, 2022 and 2021, respectively; 10,527 and 10,894 shares issued and outstanding as of december 31, 2022 and 2021, respectively | 1,000 | ||||||||||
| total shareholders’ deficit | -115,140,000 | ||||||||||
| total liabilities, redeemable convertible preferred shares and shareholders’ deficit | 97,845,000 | ||||||||||
| operating expenses: | |||||||||||
| research and development | 36,193,000 | ||||||||||
| general and administrative | 16,368,000 | ||||||||||
| total operating expenses | 52,561,000 | ||||||||||
| income from operations | -52,561,000 | ||||||||||
| interest and other income | 1,257,000 | ||||||||||
| income before benefit from income taxes | -51,304,000 | ||||||||||
| benefit from income taxes | 17,000 | ||||||||||
| net income | -51,321,000 | ||||||||||
| less: accretion of redeemable convertible preferred shares to their redemption value | -1,515,000 | ||||||||||
| less: excess of the fair value of the consideration paid over the carrying value of redeemable noncontrolling interest | |||||||||||
| net income attributable to ordinary shareholders | -52,836,000 | ||||||||||
| net income per share | -5,510 | ||||||||||
| weighted-average ordinary shares used in computing net income per share attributable to ordinary shareholders, basic and diluted | 9,584,000 | ||||||||||
| other comprehensive loss: | |||||||||||
| unrealized gain on investments | -110,000 | ||||||||||
| total other comprehensive gain | -110,000 | ||||||||||
| comprehensive loss | -51,431,000 |
We provide you with 20 years of balance sheets for Structure Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Structure Therapeutics. Explore the full financial landscape of Structure Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Structure Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.